KLRS — Kalaris Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Allovir Inc - On June 5 Entered Into A Termination Of Sublease Agreement With AMAG Pharmaceuticals, Inc
Allovir Inc reports results for the quarter ended in January - Earnings Summary
Allovir Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Allovir Says Pursuant To Letter From Nasdaq, Allovir Is Not In Compliance With Nasdaq Listing Rule 5450(A)(1)
Allovir Inc expected to post a loss of 43 cents a share - Earnings Preview
Brief: Allovir Inc- On January 1, Approved Reduction Of Its Workforce By Approximately 95%
U.S. STOCKS ON THE MOVE-Cidara Therapeutics, Senti Bio, Lumentum Holdings
U.S. STOCKS ON THE MOVE-Newmont Corp, Ansys, Karuna Therapeutics
AlloVir falls on scrapping antiviral cell therapy trials, plans to explore options
AlloVir scraps late-stage studies testing lead cell therapy (updated)
Brief: AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel
AlloVir scraps late-stage studies testing antiviral cell therapy
U.S. RESEARCH ROUNDUP- Booking Holdings, Eli Lilly, Markel Group
Allovir Inc reports results for the quarter ended in September - Earnings Summary
Brief: Allovir Q3 EPS USD -0.39
Allovir Inc expected to post a loss of 42 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Airbnb, Cummins, Meta Platforms
Allovir Inc reports results for the quarter ended in June - Earnings Summary
Brief: Allovir Q2 EPS USD -0.48